Renaissance Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$33.3M Sell
153,106
-3,348
-2% -$743K 1.39% 21
2025
Q4
$35.7M Sell
156,454
-1,494
-0.9% -$340K 1.44% 25
2025
Q3
$36.6M Buy
157,948
+9,453
+6% +$1.92M 1.38% 23
2025
Q2
$27.6M Sell
148,495
-3,467
-2% -$644K 1.07% 53
2025
Q1
$31.8M Buy
151,962
+147,449
+3,267% +$28.7M 1.4% 28
2024
Q4
$802K Sell
4,513
-546
-11% -$100K 0.03% 178
2024
Q3
$999K Buy
5,059
+1,705
+51% +$318K 0.04% 172
2024
Q2
$575K Buy
3,354
+24
+0.7% +$3.98K 0.02% 225
2024
Q1
$606K Sell
3,330
-58
-2% -$10K 0.02% 220
2023
Q4
$525K Sell
3,388
-725
-18% -$106K 0.02% 220
2023
Q3
$613K Sell
4,113
-40
-1% -$5.87K 0.03% 217
2023
Q2
$560K Sell
4,153
-463
-10% -$67.9K 0.02% 221
2023
Q1
$736K Sell
4,616
-840
-15% -$128K 0.03% 216
2022
Q4
$882K Sell
5,456
-1,661
-23% -$255K 0.04% 209
2022
Q3
$955K Sell
7,117
-537
-7% -$77.1K 0.05% 199
2022
Q2
$1.17M Sell
7,654
-94
-1% -$14.4K 0.06% 164
2022
Q1
$1.26M Sell
7,748
-80
-1% -$11.6K 0.06% 152
2021
Q4
$1.06M Sell
7,828
-249,920
-97% -$29.5M 0.04% 182
2021
Q3
$27.8M Buy
257,748
+6,138
+2% +$701K 1.2% 44
2021
Q2
$28.3M Sell
251,610
-4,883
-2% -$550K 1.19% 45
2021
Q1
$27.8M Sell
256,493
-4,100
-2% -$439K 1.17% 43
2020
Q4
$27.9M Sell
260,593
-9,567
-4% -$919K 1.2% 36
2020
Q3
$23.7M Sell
270,160
-8,002
-3% -$753K 1.09% 52
2020
Q2
$27.3M Sell
278,162
-9,443
-3% -$831K 1.3% 24
2020
Q1
$21.9M Sell
287,605
-5,996
-2% -$511K 1.22% 27
2019
Q4
$26M Buy
293,601
+7,170
+3% +$595K 1.07% 45
2019
Q3
$21.7M Sell
286,431
-1,465
-0.5% -$100K 0.92% 55
2019
Q2
$20.9M Buy
287,896
+37,580
+15% +$2.95M 0.85% 55
2019
Q1
$20.2M Buy
250,316
+21,328
+9% +$1.74M 0.81% 55
2018
Q4
$21.1M Sell
228,988
-52,511
-19% -$4.62M 0.97% 38
2018
Q3
$26.6M Buy
281,499
+9,277
+3% +$880K 0.93% 51
2018
Q2
$25.2M Buy
272,222
+6,186
+2% +$604K 0.9% 52
2018
Q1
$25.2M Buy
+266,036
New +$29.2M 0.86% 55

Other funds holding ABBV

Renaissance Group's ABBV Position: Q1 2026 in Review

Renaissance Group reduced its AbbVie (ABBV) stake by 2.1% in Q1 2026, selling an estimated $743K and leaving 153,106 shares worth $33.3M. The position accounts for 1.39% of the portfolio, ranked #21.

Renaissance Group first reported a position in ABBV in Q1 2018 and has held it in 33 quarters since. The position peaked at $36.6M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Renaissance Group held 153,106 shares of AbbVie worth $33.3M as of Q1 2026.
  • Renaissance Group sold 3,348 AbbVie shares in Q1 2026, an estimated $743K.
  • AbbVie made up 1.39% of Renaissance Group's portfolio in Q1 2026, its #21 holding.
  • Renaissance Group first reported a position in AbbVie in Q1 2018 and has held it in 33 quarters since.
  • Renaissance Group's AbbVie position peaked at $36.6M in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Renaissance Group's 13F filing for Q1 2026, filed 13 May 2026.